|Sapelizumab is an investigational humanized monoclonal antibody targeting the IL-6 receptor, with immunomodulatory potential. This antibody is an improved version of tocilizumab, with enhanced antigen-neutralizing ability and pharmacokinetics suitable for less frequent administration .
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide BLAST searches reveal identical matches between the heavy and light chain sequences as annotated in IMGT and SEQ IDs 26 and 29 respectively claimed in patent US8562991 . This matches sapelizumab to the Fv4-M73 construct in the patent.